TSG Advice Partners LLC Purchases New Stake in Gilead Sciences, Inc. $GILD

TSG Advice Partners LLC acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the third quarter, HoldingsChannel.com reports. The fund acquired 6,170 shares of the biopharmaceutical company’s stock, valued at approximately $920,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. BlackRock Inc. purchased a new stake in shares of Gilead Sciences during the 2nd quarter worth $15,393,785,000. Legal & General Group Plc acquired a new position in shares of Gilead Sciences during the second quarter worth $1,316,606,000. Deutsche Bank AG acquired a new position in shares of Gilead Sciences during the second quarter worth $918,387,000. Jupiter Topco LLC purchased a new position in Gilead Sciences in the second quarter valued at $448,021,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Gilead Sciences in the second quarter valued at $398,905,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $145.02, for a total transaction of $725,100.00. Following the completion of the sale, the director directly owned 10,066 shares of the company’s stock, valued at $1,459,771.32. This trade represents a 33.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $156.22, for a total transaction of $468,660.00. Following the completion of the transaction, the chief financial officer owned 161,096 shares in the company, valued at approximately $25,166,417.12. This trade represents a 1.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 126,881 shares of company stock valued at $19,252,455. 0.30% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of analysts have weighed in on GILD shares. Citigroup raised their price target on Gilead Sciences from $165.00 to $188.00 and gave the company a “buy” rating in a research note on Friday. Morgan Stanley upped their price objective on Gilead Sciences from $163.00 to $183.00 and gave the stock an “overweight” rating in a research report on Friday. Leerink Partners downgraded Gilead Sciences from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $146.00 to $127.00 in a report on Tuesday, July 21st. Zacks Research lowered Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 29th. Finally, Barclays decreased their target price on Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 29th. Twenty-three analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $169.74.

Gilead Sciences Price Performance

Shares of GILD opened at $170.33 on Tuesday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. Gilead Sciences, Inc. has a fifty-two week low of $116.88 and a fifty-two week high of $175.65. The firm has a 50-day simple moving average of $151.36 and a 200-day simple moving average of $140.03. The company has a market capitalization of $211.20 billion, a price-to-earnings ratio of -53.90 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.19 by $0.36. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%. The firm had revenue of $8.30 billion for the quarter, compared to analysts’ expectations of $7.81 billion. During the same quarter in the previous year, the firm posted $2.47 EPS. The firm’s revenue for the quarter was up 6.8% on a year-over-year basis. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post -1.03 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be issued a $0.82 dividend. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 1.9%. Gilead Sciences’s payout ratio is presently -103.80%.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead said it will present late-breaking clinical data and real-world evidence from more than 50 studies at HIV Glasgow 2026 on November 8–11. Updates on HIV therapies, its development pipeline and strategic collaborations could provide catalysts if the results reinforce the company’s leadership in HIV treatment. Gilead to Present Late-Breaking Clinical Data and Real-World Evidence at HIV Glasgow
• Positive Sentiment: Analysts have raised several Gilead price targets, including targets of $175, $181, $183, $188, $190 and $200. Separately, an updated fair-value estimate rose from $158.65 to $165.31, reflecting improved views of third-quarter execution, the HIV business and pipeline assets. Gilead Sciences Price Target Raised to $200.00 Gilead Stock Fair Value Edges Higher After Analyst Target Increases
• Positive Sentiment: Gilead continues to receive favorable analyst attention, including a Morgan Stanley Buy rating and inclusion among healthcare stocks described as having Strong Buy ratings and high quantitative scores. Gilead Sciences Receives a Buy from Morgan Stanley
• Neutral Sentiment: Former Gilead U.S. Medical Affairs head Dean Hakanson joined GOA Therapeutics as chief medical officer. The move highlights executive experience gained at Gilead, but it does not directly change Gilead’s operations or financial outlook. Former Gilead Head of U.S. Medical Affairs Joins GOA Therapeutics
• Negative Sentiment: One recent earnings analysis characterized Gilead’s outlook as mixed: revenue guidance was raised, but the EPS outlook worsened. That contrast could limit upside by raising concerns about profitability even as the HIV business remains strong. Gilead Sciences Q3 2026 Earnings Analysis

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.